Orthoprosthetic provision constitutes one of the benefits of the National Health System as set out in Annex VI to Royal Decree 1030/2006 of 15 September establishing the common service portfolio of the System National of Health and the procedure for its updating. This rule points to the contents of the portfolio of common services of orthoprosthetic provision comprising surgical implants, external prostheses, wheelchairs, orthotheses and special orthoprostheses, determining the groups, sub-groups and, where appropriate, approved codes for each of them.

For its part, the Royal Decree-Law 16/2012 of April 20, of urgent measures to guarantee the sustainability of the National Health System and improve the quality and safety of its benefits, amends Article 8 of the Law 16/2003, of 28 May, of cohesion and quality of the National Health System, in such a way that a supplementary common portfolio is different in which is included the orthoprosthetic delivery performed by ambulatory dispensation. It also provides that the percentage of the user's contribution to this additional portfolio will be governed by the same rules governing the pharmaceutical supply, based on the calculation basis for the final price of the product and without the application of the the same amount limit to this contribution. In this way, it differs in the context of the orthoprosthetic provision of the one provided to the insured persons on an outpatient basis, which is part of the supplementary benefits subject to the user's contribution, of which it is used in healthcare facilities without user input, primarily surgical implants.

On the other hand, the actual decree-law provides that the orthoprosthetic provision is the object of the establishment of maximum amounts of funding, in order to achieve greater efficiency and homogeneity in the provision. In addition, it is essential to fix a maximum amount applicable to the entire State, in order to ensure that when the user's contribution rates are applied, there will be no equity problems in the different management areas.

This royal decree aims to make effective the forecasts contained in the aforementioned Royal Decree-Law 16/2012, by establishing the basis for determining the content of the additional outpatient and the outpatient on the basis of Article 124 of Law 53/2002 of 30 December 2002 on the application of the provisions of Article 124 of the Treaty on European Union to the provision of services for the provision of services to the public, tax, administrative and social order.

To do this, it is considered necessary to create the Offer of orthoprosthetic products that can be financed by the National Health System and to establish the criteria for the inclusion of the products in this Offer. All this with the aim of providing a more rational delivery to the users of the National Health System.

In order to fix the maximum amounts of financing for the orthoprosthetic products included in the offer of the National Health System, some types of products with similar characteristics will be established by ministerial order. of each code approved in the case of external orthoprostheses, or of each sub-group, in the case of surgical implants, giving each type a maximum amount of funding. The determination of the types of products for the entire ortho-prosthetic provision may be made gradually, as appropriate information is available, starting with the approved codes of external orthoprostheses and the sub-groups of surgical implants that are selected according to the consumption and the ease and feasibility of their approach.

The fixing of maximum amounts of funding should not be an obstacle to the inclusion in the Offering of innovative products. Products with non-relevant changes do not require the application of the procedure for updating the service portfolio, which is regulated by Order SCO3422/2007 of 21 November 2007, for which the procedure for updating the common services portfolio of the National Health System, although if these changes have an impact on the cost of the products, they could lead to the creation of a new type of product.

On the other hand, the regulation of medical devices provides for an exceptional procedure for the express and individualized authorization of medical devices in the interest of health in cases where they do not exist. available therapeutic or diagnostic alternatives that comply with the regulation of medical devices, after justification of the need and benefits by the appropriate specialists. This procedure is covered by Community directives and applies in all countries (humanitarian clause), which is why this rule provides that this case is outside its scope.

In order to be able to make timely assessments of the impact of the maximum amounts of funding, the input of the user and other measures that may be taken in respect of this benefit, it is necessary have information on the consumption of ortho-prosthetic products in the National Health System. In addition, the information on maximum amounts of funding should be made available to the managers of the orthoprosthetic provision. For this reason, a section on information on the provision of orthoprosthetic services is included.

Finally, the royal decree includes an article referring to the obligations of manufacturers, marketers or distributors, with the objective that the orthoprosthetic delivery can be provided to the users of the system National of Health with adequate guarantees.

Therefore, this rule is aimed primarily at facilitating access to a more rational, efficient and equitable provision for patients who require an ortho-prosthetic product, by setting criteria for inclusion. in the Offer of the most suitable products to meet their needs and the establishment of maximum amounts of funding.

This royal decree has the report of the Advisory Committee of the National Health System and the Interterritorial Council of the National Health System. In its processing it has been submitted to the autonomous communities and the cities of Ceuta and Melilla, of the affected sectors and of the Council of Consumers and Users and to the previous report of the Spanish Agency of Data Protection.

In its virtue, on the proposal of the Minister of Health, Social Services and Equality, with the prior approval of the Minister of Finance and Public Administrations, in agreement with the Council of State and after deliberation of the Council of Ministers at their meeting on 2 November 2012,

DISPONGO:

Article 1. Object.

The object of this royal decree is to set the basis for:

1. Determine the content and contribution of the supplementary common portfolio of orthoprosthetic delivery.

2. º Set maximum funding amounts for each type of product included in the orthoprosthetic delivery.

All this, in order to provide a more rational, equitable and efficient delivery to the users of the National Health System.

Article 2. Definitions.

For the purposes of this royal decree is understood by:

1. Orthoprosthetic performance: It consists in the use of medical devices, implantable or not, the purpose of which is to completely or partially replace a body structure, or to modify, correct or facilitate its function. It will comprise the precise elements to improve the quality of life and autonomy of the patient. (Article 17 of Law 16/2003, of 28 May, of cohesion and quality of the National Health System).

2. Additional common portfolio of orthoprosthetic provision: Set of external prostheses, wheelchairs, orthotheses and special orthoprostheses of outpatient dispensing and subject to input from the user, financed by the National Health System, including those products that are subject to a loan or rental scheme according to the rules of the corresponding Autonomous Community.

3. Ortho-prosthetic product: Each of the trademarks of a medical device which has the consideration of an external surgical or orthoprosthesis implant, in accordance with the provisions of Annex VI to Royal Decree 1030/2006, of 15 September, by the common service portfolio of the National Health System and the procedure for updating it. In the case of custom-made products, the generic name describing the product is considered as an ortho-prosthetic product.

4. Offer of orthoprosthetic products from the National Health System (hereinafter "Offer"): A set of orthoprosthetic products that can be financed by the National Health System.

5. Product type: Each of the product sets with similar characteristics, designs and functionalities within each approved code in the case of external orthoprostheses and each sub-group in the case of surgical implants, of Annex VI of Royal Decree 1030/2006 of 15 September, in which the orthoprosthetic products included in the Offer are classified.

6. Company: Manufacturer, marketer or distributor of orthoprosthetic products.

7. Maximum amount of funding: Maximum amount set for each type of product for the purposes of its financing by the National Health System, including, where appropriate, the user's contribution. In the case of external orthoprostheses provided through orthopaedics establishments, the maximum amount of funding shall include the margins of distribution and the dispensing establishments and taxes, as well as costs of individual adaptation or elaboration, where appropriate. When it comes to surgical implants, it will refer to the company's sales price including taxes.

8. Offer Price: Price proposed by the company and accepted by the Ministry of Health, Social Services and Equality for each orthopaedic product offered to the National Health System, which must be equal to or less than the maximum amount of funding. It includes taxes and, in the case of supplementary orthoprosthetic provision, also distribution margins and dispensing establishments, as well as costs of adaptation or individualised processing.

9. Managers of orthopaedic services: Health administrations of the Autonomous Communities, National Institute of Health Management (INGESA), Social Institute of the Navy, where appropriate, and General Mutuality of Civil Servants of the State (MUFACE), Social Institute of the Armed Forces (ISFAS) and General Judicial Mutuality (MUGEJU) (hereinafter, mutual civil servants) in the case of outpatients, as well as the corresponding hospitals in the case of patients entered.

10. Orthoprosthetic Delivery Catalogue: Relation of ortho-prosthetic products or types of products that each person responsible for orthoprosthetic provision selects from the Offer to facilitate the orthoprosthetic delivery in their respective management scope.

11. Financial amount: Amount to be paid by the orthoprosthetic delivery persons for the ortho-prosthetic products or types of products listed in their respective catalogues, including taxes and, where applicable, the distribution and distribution margins dispensing establishments, as well as the cost of adaptation or individual processing, which must be equal to or less than the offer price.

Article 3. Content of the additional common portfolio of orthoprosthetic delivery.

1. The content of the additional common portfolio shall be included in the common catalogue to be drawn up by order of the person holding the Ministry of Health, Social Services and Equality, after agreement of the Interterritorial Council of the National System Health, taking into account the safety, efficacy, effectiveness and efficiency of the products, as well as the advantages and alternatives of care, the care of groups less protected or of risk, the social needs and their economic impact organizational.

2. This additional ortho-prosthetic catalogue shall constitute the common portfolio of services which, as a minimum, must be provided by all the autonomous communities, INGESA, the Social Institute of the Navy where appropriate and the mutual societies of officials, on the basis of its preparation as provided for in Annex VI to Royal Decree 1030/2006 of 15 September.

3. In the common catalogue, the cases of special prescription in which the products are to be indicated by optional units designated for the purpose by the respective autonomous community, INGESA, Social Institute of the Navy, will be indicated. (a) the right to the right of the person to be a member of the staff of the staff. Products which are considered to be fully tailor-made shall also be indicated.

4. The autonomous communities shall determine the requirements to be met by the orthopaedics dispensing establishments in order to be suppliers of the supplementary orthoprosthetic supply portfolio and the groups and/or sub-groups of products which may provide each of them to the users of the National Health System.

5. The autonomous communities and the mutual societies of officials may include in their catalogues of orthopaedic supply products or types of products not covered by the common catalogue, provided that:

a) Set the required additional resources for this,

(b) have the prior assurance of financial sufficiency in the context of compliance with the budgetary stability

,

(c) the corresponding autonomous community report, in a reasoned manner and prior to its incorporation, to the Interterritorial Council of the National Health System, in accordance with Article 8d. 4 of Law 16/2003, of 28 May, of cohesion and quality of the National Health System.

Article 4. Offer of orthoprosthetic products from the National Health System.

1. The Offer of Ortho-prosthetic Products will collect products belonging to the approved codes of the common catalogue of external orthoprostheses and to the subgroups of surgical implants that meet the criteria to be able to be financed by the National Health System referred to in Article 7.

2. This Offer will be managed by the General Directorate of the Basic Portfolio of Services of the National System of Health and Pharmacy, as the body responsible for the management of benefits.

3. The types of products in which the products included in the Offering shall be classified shall be fixed by order of the person holding the Ministry of Health, Social Services and Equality.

4. Those responsible for the provision of orthoprosthetic services, for the purpose of drawing up their respective catalogues, shall select among those products which are included in the Offering.

5. Products belonging to groups or sub-groups or approved codes not referred to in Annex VI to Royal Decree 1030/2006 of 15 September 2007 shall comply with the provisions of Order SCO3422/2007 of 21 November 2007, develops the procedure for updating the portfolio of common services of the National Health System, in the framework of Law 16/2003, of 28 May, of cohesion and quality of the National Health System.

6. Products made entirely by their own characteristics shall not be offered by the manufacturer, but if they are classified as generic in type and subject to maximum amounts of funding.

Article 5. Maximum amounts of funding in the orthoprosthetic provision.

1. By order of the person holding the Ministry of Health, Social Services and Equality, on a proposal from the Advisory Committee for the Orthoprosthetic Delivery and after agreement of the Interterritorial Council of the National Health System, the the maximum amount of funding for each of the types of orthopaedic products eligible for funding by the National Health System.

2. For the establishment of maximum amounts of funding, the characteristics of the design of the products, their functionality and performance, the population groups to which they are intended, the benefits to which they are intended, will be assessed among other aspects. represent the treatment, recovery and quality of life of patients, their prices, their consumption, the cost-benefit that they can provide to the health system, as well as the financial amounts collected in the corresponding catalogues of the Autonomous Communities, INGESA, the Social Institute of the Navy and mutual societies officials. In the case of surgical implants, the adequacy of the surgical technique and the facilitation of implantation will also be considered.

3. The maximum amounts of funding shall be taken into account, among other criteria, to decide on the inclusion of an ortho-prosthetic product in the National Health System Offering.

4. Products whose proposed price to the National Health System exceeds the maximum amount of funding corresponding to their product type will not be included in the Offer.

5. However, if a user is indicated by the specialist a particular type of external orthoprosthesis product included in the service portfolio, a product corresponding to the type that does not know will be purchased from the National Health System. It is included in the offer exclusively for exceeding the maximum amount of financing, if provided for in the regulations of the corresponding autonomous community, INGESA, Social Institute of the Navy or mutual of officials. In that case, the user shall pay the difference between the maximum amount of financing corresponding to the product type and the selling price of the product purchased, in addition to the corresponding contribution, applied on the maximum amount of financing of your product type.

6. In the case of tailor-made products, a maximum amount of financing shall be established for the types of the generic describing the product. This maximum amount shall include the costs of tailor-made processing, adaptation to the patient, establishment margins and taxes.

7. The offer prices will be the maximum reference for the autonomous communities, the INGESA, the Social Institute of the Navy and the mutual societies of officials, in their respective management areas, in order to establish their financial amounts, both for products to be provided by orthopaedic establishments, such as those purchased in healthcare facilities.

Article 6. Updating of the maximum amounts of funding.

1. The Advisory Committee for the Orthoprosthetic Provision shall appraise annually, in the light of the evolution of consumption relating to orthoprosthetic provision, variations in the prices of the offer, the costs of orthopaedic products, their cost-benefit, as well as those other factors which may have an impact on the cost of the orthoprosthetic provision, the desirability of carrying out a review of the maximum amounts of funding, in order to adapt them to the health reality of each moment, the socio-economic situation and the needs of the users of the National Health System. In addition, where exceptional circumstances determine a substantial variation in the cost of ortho-prosthetic products, whether or not their increase is to be reduced, it shall assess whether a review of the maximum amounts of the products is appropriate. financing for the types of products concerned.

2. Following this assessment, the Advisory Committee shall draw up the appropriate proposal, which shall be submitted to the Commission for Benefits, Assurance and Financing. In the light of this proposal, the person holding the Ministry of Health, Social Services and Equality, after agreement of the Interterritorial Council, shall decide whether or not to review the maximum amounts of funding.

3. The maximum amounts of funding shall be updated when tax changes affecting orthopaedic products occur.

Article 7. Criteria for the inclusion of orthoprosthetic products in the Offering.

Only orthoprosthetic products that meet all of the following requirements will be included in the Offering:

a) Meet the requirements set out in the current health care legislation.

b) Corresponding to some of the groups or subgroups of surgical implants, or of the approved external orthoprosthesis codes, listed in Annex VI to Royal Decree 1030/2006 of 15 September.

(c) Belong to any of the types of products to be determined, in accordance with Article 4.3.

d) To clearly reflect on the labelling the indications of the product and not to include phrases, drawings or other graphic reasons that lead to confusion regarding the indications, or contain advertising of other products.

e) Having a generic name accompanied by a trade mark or the name of the company owner of the product or a fancy name.

(f) Not having a name equal to or similar to that of other financial or non-financial orthoprosthetic products, except in the case of the generic name referred to in paragraph e), or of medicinal products, that of other medical devices or to the dietetic products, so as not to induce confusion. The name must also not lead to errors in relation to its particulars.

g) Do not exceed the price proposed by the company the maximum amount of financing that would correspond to it according to its type of product.

h) Do not advertise addressed to the general public.

i) Meet the technical requirements developed by the Ministry of Health, Social Services and Equality for each type of product, on a proposal from the Advisory Committee for Orthoprosthetic Delivery.

Article 8. Procedure for the inclusion, alteration and exclusion of the Offering of orthoprosthetic products.

1. The procedure for the inclusion of an orthoprosthetic product in the Offer, for the alteration of its conditions of use or for the exclusion of the same shall be established by order of the person holder of the Ministry of Health, Social Services and Equality, on a proposal from the Commission of Benefits, Assurance and Financing, prior to the Interterritorial Council of the National Health System.

2. The company that wants an orthoprosthetic product to be included in the Offer for financing by the National Health System must request the Ministry of Health, Social Services and Equality, for which it will have to send to the General Portfolio of Services of the National System of Health and Pharmacy, an express request for inclusion in the Offer and assignment of identification code.

3. This general address will determine whether or not the product is eligible to be included in the Offering and, if so, will assign an identifying code to it.

4. The General Directorate of the Basic Portfolio of Services of the National System of Health and Pharmacy may also determine the exclusion of a product included in the Offer if one of the following circumstances is present:

a) Stop meeting any of the requirements set out in the legislation in force.

b) The type of product, approved code, subgroup or group to which it belongs is excluded from the financing, in accordance with the procedure laid down by Order SCO3422/2007 of 21 November.

c) Your risk/benefit balance is unfavorable.

d) Performs advertising directed to the general public.

e) Requesting exclusion from the incumbent company.

Article 9. User input.

1. As a general rule, the additional portfolio of orthoprosthetic services is subject to the user's contribution, with a scheme similar to that of the pharmaceutical provision, based on the calculation of the price of the product. The percentage of the user's contribution shall be governed by the same rules governing the pharmaceutical provision and without applying the same amount limit to this contribution.

2. As a result, the percentage of user input will be as follows:

(a) 60 per cent of the price of the product offering for users and their beneficiaries whose income is entered in the accounts of the general liquidable base and the savings in the income tax return Natural Persons is equal to or greater than 100,000 euros.

(b) 50% of the price of the product offering for the persons holding the condition of the insured person and the beneficiaries whose income is entered in the accounts of the general liquidable base and the savings of the Tax on the income of the physical persons is equal to or greater than 18,000 euros and less than 100,000 euros.

c) 40 percent of the product's Offer price for persons who have the status of an active insured person and their beneficiaries and are not included in paragraphs (a) or (b).

(d) 10 percent of the product's offer price for persons who have the status of insured as Social Security Pensioners and their beneficiaries, with the exception of the persons listed in subparagraph (a).

e) 10 percent of the product's Offer price on products belonging to the reduced-contribution sub-groups listed in the Annex.

3. By order of the person holding the Ministry of Health, Social Services and Equality, after a report from the Interterritorial Council, the maximum limit of the contribution to be paid by the users referred to above shall be established. (b), (c), (d) and (e).

4. Users and their beneficiaries who at the time of the dispensation belong to one of the following categories shall be exempt from contributions:

a) Affected by toxic syndrome.

b) Persons with disabilities who are beneficiaries of the special social and economic benefits system provided for in Article 12 of Law 13/1982 of 7 April 1982 on the social integration of persons with disabilities; other persons with disabilities who are also in cases of exemption covered by their specific rules.

c) Persons receiving social integration income.

d) Non-contributory pension recipients.

(e) Parates who have lost the right to receive unemployment benefit as long as their situation exists.

(f) Persons who require treatment arising from occupational accidents or occupational diseases, although their funding shall be borne by the relevant Working Accident Mutua of the National Security Institute. Social or the Social Institute of the Navy.

5. Persons holding or benefiting from special social security schemes managed by the mutual funds of officials shall contribute 30% to the limit laid down for the users of paragraph 2 (c), except for products belonging to the sub-groups for which the contribution is reduced, in which the provisions of paragraph 2 shall apply. (e) and for treatments resulting from an accident in the event of a service or occupational disease, which shall be exempt from input.

Article 10. Information on orthoprosthetic delivery.

1. The General Directorate of the Basic Portfolio of Services of the National System of Health and Pharmacy will report periodically on the products included in the Offer, as well as their offer prices, to the Autonomous Communities, to the INGESA, to the Social Institute of the Navy, the mutual societies of officials and those other agents directly involved in the management of the orthoprosthetic provision.

2. In order to have data on the evolution of the orthoprosthetic provision and the impact of the measures adopted on this provision, the health services of the autonomous communities, the INGESA, the Social Institute of the Navy and the Member States shall forward information on the consumption of ortho-prosthetic products in their field, with the frequency and format agreed in the Advisory Committee for the Orthoprosthetic Provision, to the Directorate-General of the Basic Portfolio of Services of the National System of Health and Pharmacy, who will manage the aggregated information of the National Health System as a whole.

3. The aggregated information on the use of orthoprosthetic delivery, both supplied through orthopaedic and through health centres, shall be made available to the members of the Advisory Committee for the Orthoprosthetic Provision and the Commission In addition to the information provided by the Commission, the Commission has taken into account the information provided by the Commission on the basis of the information provided by the Commission. The purpose of the transfer shall be to dissociate the data from prior dissociation.

4. It is up to the Autonomous Communities, the INGESA, the Social Institute of the Navy and the mutual societies of officials to evaluate the prescriptions for areas, zones, therapies, population groups and other circumstances in their respective areas. areas of competence. The Ministry of Health, Social Services and Equality shall establish the coordination mechanisms to enable the use of ortho-prosthetic products and to adopt measures for information and promotion of the rational use of such products.

Article 11. Obligations of companies.

1. The company that has a high in the Offer an orthoprosthetic product will have to keep it in the market and will guarantee the supply necessary to facilitate the delivery of the product to the users of the National System of Health. In case you anticipate that you are not going to be able to do so, you will need to request the drop in the Offer.

2. The information that the companies direct to the healthcare professionals on the orthoprosthetic products included in the Offering may not contain messages that may lead to confusion about the indications for which the product is bankable, and must comply with the provisions of Law 29/2006 of 26 July on guarantees and the rational use of medicinal products and medical devices, in Law 34/1988 of 11 November, General Advertising and other current legislation.

3. Undertakings shall provide information on the technical and economic aspects required of them by the Ministry of Health, Social Services and Equality only for the purposes of fixing maximum amounts of funding or other aspects regarding the inclusion of a product in the Offering. The information provided by this section of the General Administration of the State shall be confidential.

4. Companies shall ensure an adequate technical service of their products (repair and spare parts), which shall be maintained for a reasonable period of time, depending on the average service life of each product.

Additional disposition first. Use of products under express authorization.

The provisions of this royal decree do not affect the use in the National Health System of medical devices to which the Spanish Agency for Medicinal Products and Sanitary Products has granted an express authorization. individualized in the interest of health protection, in accordance with the provisions of the regulation of medical devices.

Additional provision second. Orthoprosthetic provision of special social security schemes managed by the mutual societies of civil servants.

The Autonomous Communities and the INGESA shall facilitate the provision of orthoprosthetic services to persons who are the holders or beneficiaries of special social security schemes managed by the mutual societies of officials who have been been assigned to their corresponding health services by the established procedure. This benefit shall be subject to the same conditions as the users of the relevant Community or INGESA, except as regards the contribution provided for in Article 9.5.

Single transient arrangement. Orthoprosthetic delivery catalogs.

1. As long as the maximum amounts of funding and the limits of contribution are established by order of the person holding the Ministry of Health, Social Services and Equality, the Autonomous Communities, the INGESA, the Social Institute of the Navy where appropriate and the mutual funds of officials may continue to apply their specific rules on the provision of orthoprosthetic services and select the products they deem most appropriate in their catalogues, within the framework of the Royal Decree 1030/2006, dated September 15.

2. For those products, the users ' contribution shall continue to be as set out in Annex VI to that Royal Decree 1030/2006.

Single repeal provision. Regulatory repeal.

As many provisions of equal or lower rank are repealed, they oppose the provisions of this royal decree, and, in any case, the aspects concerning the contribution of the user listed in Annex VI of the Royal Decree 1030/2006, of 15 September, establishing the portfolio of common services of the National Health System and the procedure for its updating.

Final disposition first. Competence title.

This royal decree is issued in accordance with the provisions of article 149.1.16 of the Constitution, which gives the State exclusive competence in the field of basic and general health coordination.

Final disposition second. Regulatory enablement.

The person holding the Ministry of Health, Social Services and Equality, prior to the report of the Interterritorial Council of the National Health System, is enabled to dictate how many provisions the application and development require. of this royal decree, in particular as regards the establishment of product types and their maximum amounts of financing, as well as the updating of the sub-groups of reduced contribution contained in the Annex and the fixing of the maximum contribution limits.

Final disposition third. Entry into force.

This royal decree will enter into force on the day following its publication in the "Official State Gazette".

Given in Madrid, on November 2, 2012.

JOHN CARLOS R.

The Minister of Health, Social Services and Equality,

ANA MATO ADROVER

ANNEX

Subsets of reduced-input orthoprosthetic products

1. External prostheses.

06 18 03

Partial hand protesis, including finger prostheses.
06 18 06	Doll disarticulation protein.
06 18 09	Transradial Prothesis (below the elbow)
06 18 12	Elbow disarticulation protesis.
06 18 15	Transhumeral Prothesis (above elbow)
06 18 18	Shoulder Disarticulation (PDH) Prothesis
06 18 21	Upper room amputation protein (interescapothoracic) (PACS).
06 18 24	Hand Protesis.
06 18 27	18 30
	06 18 30
06 18 33	elbow joints.
06 18 36	Shoulder joints.
06 24 03	Prothesis partial standing, including finger prostheses
24 06	Ankle disarticulation protein
06 24 09	Transtibial Prothesis (below knee)
06 24 12	Knee disarticulation protein
06 24 15	Transfemoral (over-the-knee) protesis
24 18	Prothesis of hip disarticulation
06 24 21	24 27
06 24 27	prosthetic feet, except feet of "large energy storage" and similar
06 24 30	Rotors.
06 24 33	knee joints
06 24 36	Hip joints.
06 24 39	Tibials.
06 24 42	Femoral Encages.
06 24 48	Provisional Prothesis for early mobilization in lower member amputation
06 90 00	Spell for agenesies.
06 30 18	Prothesis of Breast.
06 30 30	Facial restoration protesis, including nose and/or headsets and/or eyeballs in cases of trauma, disease, or congenital malformation
06 30 33	palate protein for congenital malformations, trauma and oncological processes of the palate
21 45 00	hearing aids.

2. Wheelchairs.

12 21 00	Manual wheel chairs
12 21 27	Wheels of wheels with electric motor and electrical steering for patients with severe functional limitations of the locomotor by disease, malformation or accident
12 24 90	Recambios and Wheelchair components (only 12 24 90 003 bespoke post-ural support and 12 24 90 004 Modular postural support)

3. Orthosis.

06 03 06

Lump Orthesis, except 06 03 06 000 Semi-rigid lumbar-sacral Orthesis
06 03 09	Toraco-lumbar-sacras (dorso-lumbar) Orthesis, except 06 03 09 000 Toraco-lumbar-lumbar Orthesis
06 03 18	Orthesis cervico-toraco-lumbo-sacras.
06 12 18	Hip, knee, ankle, and foot orthosis

4. Special orthoprostheses.

	06 06	Compression benefits for arms, legs, and other parts of the body for burns, lymphedemas upper limbs, severe lower limb lymphedema and large keloids
04 33 00	Cojines to prevent pressure damage, only for patients with spinal injuries
48 06	Bipedestation appliances
04 48 21	Leatable Planes.

5. Renovation of the external components of surgical implants.